作者
Feng Peng,Lushi Tan,Lu Chen,Stephen M. Dalby,Daniel A. DiRocco,Duan Jian-jun,Minyi Feng,Guan Gong,Haiheng Guo,J. Caleb Hethcox,Lu Jin,Heather C. Johnson,Jungchul Kim,Diane N. Le,Yipeng Lin,Wenjun Liu,Shen Jun,Yimei Wan,Chengqian Xiao,Bangping Xiang,Xiang Qun,Jing Xu,Luliang Yan,Weiyi Yang,YE Hong-lin,Yanpei Yu,Jun Zhang
摘要
A four-step synthesis of the indanone core of belzutifan (MK-6482) is described. This route starts from the commodity raw material dihydrocoumarin and was successfully demonstrated on a large scale to produce indanone 11 in the synthesis of belzutifan, an FDA-approved first-in-class therapy for the treatment of patients with certain types of Von Hippel–Lindau disease-associated tumors.